CIBC Asset Management Inc Grows Position in Cencora, Inc. $COR

CIBC Asset Management Inc boosted its position in shares of Cencora, Inc. (NYSE:COR) by 3.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 66,201 shares of the company’s stock after purchasing an additional 2,316 shares during the period. CIBC Asset Management Inc’s holdings in Cencora were worth $20,678,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC grew its position in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares during the last quarter. Caldwell Trust Co purchased a new stake in Cencora in the second quarter worth $46,000. Salomon & Ludwin LLC lifted its position in shares of Cencora by 638.1% during the third quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock worth $47,000 after purchasing an additional 134 shares during the last quarter. Finally, Capital A Wealth Management LLC boosted its stake in shares of Cencora by 3,975.0% during the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after purchasing an additional 159 shares during the period. Institutional investors own 97.52% of the company’s stock.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. The trade was a 7.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 20,316 shares of company stock worth $7,151,265. Corporate insiders own 0.38% of the company’s stock.

Cencora Stock Up 0.2%

Cencora stock opened at $353.07 on Monday. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The firm has a market cap of $68.49 billion, a P/E ratio of 44.41, a P/E/G ratio of 1.68 and a beta of 0.66. The business has a fifty day moving average of $348.49 and a two-hundred day moving average of $322.22. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the business posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is currently 30.19%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on COR shares. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a report on Thursday. Mizuho increased their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, TD Cowen lifted their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average target price of $393.08.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.